Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 112 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Systemic Vasculitis Clear all

Conditions: Granulomatosis With Polyangiitis
Interventions: Airway assessment, Rheumatology assessment; Procedure
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions: CCX168; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Wegener Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Polyarteritis Nodosa, Giant Cell Arteritis, Takayasu's Arteritis, Henoch-Schoenlein Purpura, Behcet's Disease, CNS Vasculitis
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Interventions: Rituximab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 15
States / cities: Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 11 more

Conditions: Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis, Churg-Strauss Syndrome, Eosinophilic Esophagitis
Interventions: Mepolizumab; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Vasculitis, Wegener's Granulomatosis
Interventions: cyclophosphamide; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1976 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Wegener's
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: Not listed
Enrollment: 1,046 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 6
States / cities: Boston, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 3 more

Conditions: Aortitis, Cutaneous Vasculitis, Eosinophilic Granulomatosis With Polyangiitis, Giant Cell Arteritis, Granulomatosis With Polyangiitis (Wegener's), Henoch-Schonlein Purpura, IgA Vasculitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis, Churg-Strauss Syndrome
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 6
States / cities: Boston, Massachusetts • Cleveland, Ohio • Philadelphia, Pennsylvania + 2 more

Conditions: Asthma
Interventions: Benralizumab; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
Interventions: FT839; Biological
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2040
U.S. locations: 1
States / cities: Fullerton, California

Conditions: Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: Not listed
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2028
U.S. locations: 8
States / cities: San Diego, California • Denver, Colorado • Boston, Massachusetts + 5 more

Conditions: Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis
Interventions: Rituximab plus cyclophosphamide placebo (rituximab group), Cyclophosphamide plus rituximab placebo (control group), Azathioprine, Methylprednisolone (or other glucocorticoid), Prednisone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 15 Years and older
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 7
States / cities: Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more

Conditions: Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Interventions: NS-229, Placebo; Drug
Lead sponsor: NS Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Denver, Colorado • Rochester, Minnesota • Cleveland, Ohio + 4 more

Conditions: Granulomatosis With Polyangiitis (Wegener's Granulomatosis)
Interventions: Rituximab, Placebo; Drug · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Wegener's Granulomatosis
Interventions: Daclizumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Systemic Lupus Erythematosus
Interventions: Clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain; Other
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Vasculitis
Interventions: Placebo, Belimumab 10 mg/kg, Azathioprine; Biological · Drug
Lead sponsor: Human Genome Sciences Inc., a GSK Company; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 22
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 18 more

Conditions: Granulomatosis With Polyangiitis, Wegener Granulomatosis, Vasculitis
Interventions: 5 mg prednisone, 0 mg prednisone; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: ANCA Associated Vasculitis
Interventions: ENUMERATION OF CD5+ B Cells; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 85 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis, Psoriasis, Giant Cell Arteritis, Polymyalgia Rheumatica, Systemic Lupus Erythematosus, Crohn Disease, Multiple Sclerosis, Ulcerative Colitis
Interventions: Nivolumab; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 9
States / cities: Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 6 more

Conditions: Electrocardiography
Interventions: Avacopan, Moxifloxacin, Placebo for avacopan, Placebo for moxifloxacin; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Hepatic Impairment
Interventions: Avacopan; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Neuropsychiatric Systemic Lupus Erythematosus
Interventions: Not listed
Lead sponsor: Lupus Research Alliance; Other
Eligibility: 18 Years to 110 Years
Enrollment: 3,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2035
U.S. locations: 19
States / cities: Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 15 more

Conditions: Churg-Strauss Syndrome
Interventions: Rituximab, Prednisone; Drug
Lead sponsor: Fernando Fervenza; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study

A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168

Vasculitis Illness Perception (VIP) Study

An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome

Treatment of Wegener's Granulomatosis With Cyclophosphamide

Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis

VCRC Tissue Repository

Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

FT839 in Autoimmune Diseases

Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis

Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis

Daclizumab to Treat Wegener's Granulomatosis

Libman-Sacks Endocarditis as a Cause of Neuropsychiatric Systemic Lupus Erythematosus

Belimumab in Remission of VASculitis

The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach

Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis

Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants

A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Impairment

Lupus Landmark Study: A Prospective Registry and Biorepository

Rituxan in Churg Strauss Syndrome With Renal Involvement